Pegcetacoplan Continues to Reduce Geographic Atrophy Lesion Growth: 18-Month Data
DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.
Age-Related Macular Degeneration
Trials Show Promise for Intravitreal Faricimab in Retinal Disease
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
January 2022: 5 Notable Drug Approvals
Review the January 2022 notable drug approvals.
Vabysmo Approved for Wet AMD, Diabetic Macular Edema
Vabysmo is a humanized bispecific antibody that works by inhibiting the angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) pathways.
New Drug Product: Susvimo
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
Susvimo Approved for Wet Age-Related Macular Degeneration
Susvimo delivers ranibizumab via ocular implant, which is surgically inserted into the eye during a one-time, outpatient procedure and refilled every 6 months.
Faricimab Gets Priority Review for Wet AMD, Diabetic Macular Edema
The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.
7 Steps Patients Should Take to Prevent Age-Related Macular Degeneration
February is AMD and Low Vision Awareness Month. There are several modifications patients can make to their lifestyles that may help reduce their risk of AMD.
